Funding information Natera, Inc.
of fetal loss to obtain fetal cells for analysis, 13 or because it may identify CNVs of uncertain clinical significance, some women may decline CMA. Analysis of cell-free DNA in maternal plasma potentially offers an alternative, non-invasive prenatal-testing path toward the identification of targeted microdeletions; only women found to be at highrisk need to be offered invasive testing. 4, [14] [15] [16] [17] Currently, single-nucleotide polymorphism (SNP)-based noninvasive prenatal testing (NIPT) can screen for 5 clinically significant microdeletions 1 -22q11.2, 18 1p36, 19 cri-du-chat (5p15.3), 20 PraderWilli (paternal 15q11-q13), 21, 22 and Angelman (maternal 15q11-q13). 21 Previous analysis of a cohort of nearly 22 000 women referred for screening for the 22q11.2 deletion demonstrated a 0.5% screen-positive rate (SPR) and an 18% positive predictive value (PPV). 23 Here, we report for the first time the screening performance of this SNP-based NIPT for 1p36, cri-du-chat, Prader-Willi, and
Angelman microdeletion syndromes. We also update our clinical experience in screening for 22q11.2 deletion syndrome to now include over 80 000 referrals. 23 Earlier studies indicated that reflex sequencing of high-risk microdeletion test results at a higher depth of read (HDOR) may substantially reduce the false-positive rate (FPR). 17, 24 In this study, we assess the screening performance of this modification, combined with a higher quality-control confidence threshold. We compare the performance of the original and revised protocols, and use these results to estimate the prevalence of the 5 microdeletions in the test population.
| MATERIALS AND METHODS

| Study period and cohorts
A SNP-based NIPT screen for fetal chromosome abnormalities was offered clinically for the 22q11. (Table S1 , Supporting Information). 23 For each maternal blood sample, the maternal date of birth, maternal weight, gestational age, reason for testing, and informed consent were collected. Test-interpretation information, guidance on confirmatory testing options, genetic counseling, and disease-specific literature were available to test providers and patients.
| SNP-based analysis
Samples were analyzed at a Clinical Laboratory Improvement Actcertified, College of American Pathologists-accredited laboratory using previously described methodology. 4 
| Post-hoc analysis
Post-hoc analysis of test performance was performed in an internally blinded manner using a revised protocol with a higher (95%) confidence threshold for reporting a case as high-risk for a microdeletion, and reflex sequencing of high-risk cases at HDOR (≥6 million reads/ sample). 23, 24 Because the presence or absence of deletions on the paternally inherited chromosome are readily discerned at normal depth of read, only cases with a suspected deletion on the maternally inherited chromosome were reflexed to HDOR. To allow for cases without post-hoc analysis results (due to samples being unavailable for re-sequencing) in the estimation of PPV, SPR, and FPR for the revised protocol, a proportionate adjustment was made to the total number of cases tested.
| Estimation of disease prevalence in the study population
The prevalence of each microdeletion syndrome in the population was calculated as: number of affected pregnancies/(number of cases with a test result × percentage of syndromic deletions expected to be captured by test), where the numerator is the sum of the number of known TPs, the expected number of affected cases in the group with an unconfirmed outcome, and the number of known false negative cases. Prevalence was calculated using only cases for which both maternally and paternally inherited alleles could be analyzed. For these estimates, it was assumed that the proportion of affected cases among samples with unknown outcome was equal to that of cases with known outcome.
| Institutional approval
The study was exempted from institutional review board approval (Ethical & Independent Review Services, Corte Madera, CA; Study ID 14064-01).
3 | RESULTS
| Referrals
A total of 80 449 referrals were received for microdeletion screening during the study period, of which 42 326 were for the full panel of microdeletion syndromes and the remainder were limited to testing for the 22q11.2 deletion ( Figure 1 and Table S1 ). 23 Because microdeletion screening was only performed when aneuploidy screening could be successfully completed, 5511 cases were ineligible for microdeletion screening for reasons including test canceled, draw <9 weeks GA, insufficient blood volume, contamination, multiple gestations, and low fetal fraction (Table S3) Figure 1 ). An additional 6 cases received a high-risk result due to a suspected maternal deletion. Of the 283 cases identified as being at high-risk for a fetal microdeletion, follow-up information on copy-number truth was available for 153 (54.1%) cases (via invasive diagnostic testing, n = 117; postnatal diagnostic testing, n = 32; or post-miscarriage products-of-conception testing, n = 4).
Twenty-four (8.5%) of the high-risk results were TP (Table S4 ) and 129 (45.6%) were FP (Table 3) .
| 1p36, cri-du-chat, Prader-Willi and Angelman microdeletions
A total of 39 678 samples were screened for all 4 microdeletions, with varying numbers of high-risk, low-risk, and risk-unchanged cases obtained for each microdeletion (Table 2 and Figure 1 ). Considering the 4 microdeletions together, there were 215 high-risk calls of which 7 were TP, 117 were FP and 91 had unknown outcome (results for each microdeletion and for the combination of deletions are in Table 3 ). Truth was established on the basis of invasive diagnostic testing (118 cases), postnatal diagnostic testing (5 cases), or postmiscarriage products-of-conception testing (1 case). Additional details of the 7 TPs are in Table S4 . One false-negative case was reported (for cri-du-chat syndrome).
| Maternal deletions
Of the 74 938 total cases screened (whether for 22q11.2 deletion alone or for all 5 microdeletions), a fetal risk score of 50% was assigned in 6 cases due to suspected deletions in the 22q11.2 region in the mother; no case had suspected maternal deletions in any of the other interrogated regions. Follow-up information was available for 3 of these 6 cases. In 2 cases, a maternal deletion of the 22q11.2 region was confirmed, but fetal copy number was not provided. In the third case, a fetal deletion was confirmed, and although the mother's copy number for the 22q11.2 region was not assessed, she had tetralogy of Fallot and learning disabilities, both of which are associated with 22q11.2 deletion syndrome.
| Performance based on presence or absence of ultrasound abnormalities
Test performance was compared for high-risk calls with, and without, major fetal structural abnormalities detected by ultrasound prior to NIPT (Table 4) . Of the 498 cases determined to be high-risk for a fetal deletion by NIPT, 297 (59.6%) had information available about the presence/absence of ultrasound findings and 201 (40.4%) did not. Fifty-one of these cases had major fetal ultrasound anomalies present (Table S5) , of which 37 had abnormalities detected prior to NIPT. However, 260 cases had no reported ultrasound abnormalities at the time of NIPT; this includes 14 cases for which ultrasound information became available after NIPT testing was performed. As expected, PPVs were higher in cases with abnormal ultrasound findings identified prior to NIPT ( One case reported as low-risk for cri-du-chat microdeletion syndrome was a false negative. (n = 209) were as follows: 188 (90%) were continued, 7 (3%) miscarried, and 14 (7%) were terminated.
| Prevalence of microdeletions
In this study, the estimated prevalence of 22q11.2 deletion syndrome was 1 in 1255, and those for the 1p36 deletion, cri-du-chat, and Angelman syndromes ranged from 1 in 3624 to 5820 (Figure 2 ). The prevalence of Prader-Willi syndrome was not estimated due to lack of a TP case. The combined estimated prevalence of 1p36, cri-du-chat, and
Angelman microdeletions in this cohort was 1 in 1464, and for all 5 disorders combined it was 1 in 676. Details of the calculations for prevalence are presented in Appendix S1. Because there may have been additional false negative cases that did not come to attention, these prevalence rates are minimal estimates. with the original protocol; Table 5 ).
| 1p36, cri-du-chat, Prader-Willi and Angelman microdeletions
Similar improvements were seen for the other microdeletions. Considering the 1p36, cri-du-chat, Prader-Will and Angelman results together (n = 215), the revised protocol was applied to 209 (7 TP, 114 FP, and 88 unknown) cases (97.2%) determined to be high-risk a Sum of the prorated number of cases, allowing for the different number of calls for each microdeletion, calculated for 100 000 total test results.
b Sum of the rates for each microdeletion.
c Upper and lower boundaries assuming all unknown cases were TP or FP, respectively. with the original protocol (the remaining cases were unavailable for analysis; Figure 1 ). Known FP results were reduced by 86.8%
(99/114), all 7 TP remained high-risk calls, and there was a propor- (Table 5 ).
| DISCUSSION
This study extends our initial report 23 
4,23
We also show that applying a stricter quality-control confidence threshold and reflexively sequencing high-risk samples to a HDOR with the revised screening protocol reduced FPRs and increased PPVs substantially. As a result of these performance improvements, the revised protocol has been implemented commercially.
Our initial study indicated that screening for 22q11.2 deletion syndrome using the original protocol would be associated with a 0.38% FPR, an 18.0% PPV, and a prevalence of 1 in 962 in the test population. 23 In this study, with the original protocol, the FPR was 0.33%, the PPV was 15.7%, and the estimated prevalence was 1 in 1255. With a revised protocol, performance improved to a projected 0.07% FPR and 44.2% PPV. The revised protocol also exhibited relatively high PPVs for the other 4 microdeletion syndromes, although these had larger confidence intervals (Table 5 ). Because microdeletions are less prevalent than aneuploidies in NIPT cohorts, the PPVs for screening microdeletions are expected to be lower than those observed for aneuploidy. 15, 17 In fact, observed PPVs for microdeletions using the updated protocol are lower than reported NIPT PPVs for trisomy 18 and trisomy 21, and similar to those for trisomy 13 and monosomy X. 15, 27, 28 Moreover, the PPVs we observed are similar to, or better than, those observed with conventional maternal serum screening for trisomies-a bar that has been considered sufficient to justify routine use.
Prior publications have questioned the use of NIPT as a screening test for microdeletions, citing concerns about high FPRs, low sensitivities, and challenges associated with variants of unknown significance. 29, 30 However, these reports focused on whole-genome sequencing approaches that employ counting-based methodologies.
By concentrating on specific genomic regions with clinically significant deletions, the targeted nature of the SNP-based method overcomes many of the limitations discussed in these publications. 31 Furthermore, comparison of detection rates for confirmed microdeletions in clinical cohorts and ratios of maternally inherited vs de novo deletions to published ratios suggests that SNP-based methods have substantially higher sensitivity than counting-based methods. [32] [33] [34] In this study, the observed FPR for Angelman syndrome (conveyed by the maternally inherited chromosome 15q11-13 region) was substantially higher than that for Prader-Willi syndrome (conveyed by the same This study has a number of limitations. First, this is a clinically derived cohort and the patients who were selected for testing may not reflect a general obstetrical population (ie, the referral population may have been enriched for cases with a high a priori risk for a microdeletion). This was evidenced by the high percentage of TP cases with ultrasound abnormalities identified prior to performing NIPT (Table S5 ). When we estimated the PPVs for the subset of the cohort without any abnormal ultrasound findings prior to NIPT, we found lower PPVs, as expected. We recalculated the PPVs to adjust for differences in prevalence and found that the test continued to show good performance in low prevalence populations (Appendix S3 and Table S6 ). Second, we were unable to obtain follow-up data for 44% of cases in this study despite considerable efforts to gather this information. To address this issue, we calculated PPV boundary values, assuming all cases with unknown outcome were either all TP or all FP (Tables 3 and 5 ). These data indicate that even in the unlikely event that all cases with unknown outcomes are FPs, the SNP-based NIPT with the revised protocol retains PPVs similar to the performance of NIPT for trisomy 13 and monosomy X, and greater than that of maternal serum This study extends previous work 23 demonstrating that prenatal screening for the 22q11.2 deletion can be effectively performed via a SNP-based NIPT. In this study, the combined estimated prevalence for the set of microdeletion disorders in the screened population (1/676) exceeded that of Down syndrome in younger women, 36 and also that of open neural-tube defects in the US population (1/1886). 37 Additionally, PPVs and FPRs of SNP-based screening appeared to be superior to those of traditional screening methods offered to screen for Down syndrome 38 and open neural-tube defects. 39 The observed prevalences and test performance therefore exceed that of other prenatal screening tests long considered standard of care. Consistent with recent American College of Medical Genetics and Genomics guidelines, 40 our findings support offering microdeletion screening as an adjunct to existing NIPT to refine risks for these 5 clinically significant, well-characterized genetic disorders.
